Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Byeon, Seong Rim | - |
dc.contributor.author | Kim, Hyunjin Vincent | - |
dc.contributor.author | Jeon, Mijin | - |
dc.contributor.author | Ahn, Young Gil | - |
dc.contributor.author | Kim, Maeng Sup | - |
dc.contributor.author | Kong, Jae Yang | - |
dc.contributor.author | Kim, Hye Yun | - |
dc.contributor.author | Kim, Young Soo | - |
dc.contributor.author | Kim, Dong Jin | - |
dc.date.accessioned | 2024-01-20T12:04:07Z | - |
dc.date.available | 2024-01-20T12:04:07Z | - |
dc.date.created | 2022-01-10 | - |
dc.date.issued | 2013-06-01 | - |
dc.identifier.issn | 0960-894X | - |
dc.identifier.uri | https://pubs.kist.re.kr/handle/201004/127976 | - |
dc.description.abstract | Alzheimer's disease drug discovery regarding exploration into the molecules and processes has focused on the intrinsic causes of the brain disorder correlated with the accumulation of amyloid-beta. An anti-amyloidogenic bis-styrylbenzene derivative, KMS80013, showed excellent oral bioavailability (F = 46.2%), facilitated brain penetration (26%, iv) in mouse and target specific in vivo efficacy in acute AD mouse model attenuating the cognitive deficiency in Y-maze test. Acute toxicity (LD50 > 2000 mg/kg) and hERG channel inhibition (14% at 10 mu M) results indicated safety of KMS80013. (C) 2013 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.publisher | Pergamon Press Ltd. | - |
dc.subject | SOLID-PHASE SYNTHESIS | - |
dc.subject | CURCUMIN | - |
dc.subject | DRUG | - |
dc.subject | HYPOTHESIS | - |
dc.subject | PATHOLOGY | - |
dc.subject | PEPTIDE | - |
dc.title | Therapeutic and pharmacokinetic characterizations of an anti-amyloidogenic bis-styrylbenzene derivative for Alzheimer's disease treatment | - |
dc.type | Article | - |
dc.identifier.doi | 10.1016/j.bmcl.2013.02.104 | - |
dc.description.journalClass | 1 | - |
dc.identifier.bibliographicCitation | Bioorganic & Medicinal Chemistry Letters, v.23, no.11, pp.3467 - 3469 | - |
dc.citation.title | Bioorganic & Medicinal Chemistry Letters | - |
dc.citation.volume | 23 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | 3467 | - |
dc.citation.endPage | 3469 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.identifier.wosid | 000318976100070 | - |
dc.identifier.scopusid | 2-s2.0-84877586188 | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Organic | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Chemistry | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | SOLID-PHASE SYNTHESIS | - |
dc.subject.keywordPlus | CURCUMIN | - |
dc.subject.keywordPlus | DRUG | - |
dc.subject.keywordPlus | HYPOTHESIS | - |
dc.subject.keywordPlus | PATHOLOGY | - |
dc.subject.keywordPlus | PEPTIDE | - |
dc.subject.keywordAuthor | Amyloid-beta | - |
dc.subject.keywordAuthor | Alzheimer&apos | - |
dc.subject.keywordAuthor | s disease | - |
dc.subject.keywordAuthor | Aggregation inhibitor | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Behavior test | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.